Description:

Study part: PGx- Pharmacogenetic. A phase 1 single-masked, randomized (with respect to placebo), placebo-controlled, parallel-group, dose-rising study to evaluate the safety, tolerability and pharmacokinetics of repeat oral doses of GW786034 in elderly healthy volunteers. Trade Name: Votrient. Clinical Study ID: MD1103367.

Keywords:
Versions (1) ▾
  1. 7/2/18
Copyright Holder:
GlaxoSmithKline
Uploaded on:

July 2, 2018

DOI:
No DOI assigned. To request one pleaselog in.
License:
Creative Commons BY-NC 3.0
Model comments:

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for:

Item comments for:

In order to download data models you must be logged in. Please log in or register for free.

PGx- Pharmacogenetic Pazopanib Macular Degeneration MD1103367

PGx- Pharmacogenetic

  1. StudyEvent: ODM
    1. PGx- Pharmacogenetic
PGx-PHARMACOGENETIC RESEARCH CONSENT (PGx Consent)
PGx-PHARMACOGENETIC RESEARCH WITHDRAWAL OF CONSENT (PGx Withdraw)